F1063-0967 | DUSP26 inhibitor | CAS#613225-56-2

MedKoo Cat#: 525607 | Name: F1063-0967

Description:

WARNING: This product is for research use only, not for human or veterinary use.

F1063-0967 is a novel inhibitor of dual-specificity phosphatase 26 (DUSP26), inducing apoptosis in IMR-32 cell line.

Chemical Structure

F1063-0967

CAS#613225-56-2

Theoretical Analysis

MedKoo Cat#: 525607

Name: F1063-0967

CAS#: 613225-56-2

Chemical Formula: C24H24N2O5S2

Exact Mass: 484.1127

Molecular Weight: 484.59

Elemental Analysis: C, 59.49; H, 4.99; N, 5.78; O, 16.51; S, 13.23

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 400.00	2 Weeks
100mg	USD 650.00	2 Weeks
200mg	USD 1,150.00	2 Weeks
500mg	USD 2,250.00	2 Weeks
1g	USD 3,250.00	2 Weeks
2g	USD 5,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

F1063-0967; F1063 0967; F10630967; F-10630967; F 10630967;

IUPAC/Chemical Name

(Z)-2-Hydroxy-4-{6-[5-(4-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-hexanoylamino}-benzoic acid

InChi Key

RNICWTYEMLCCAS-MOSHPQCFSA-N

InChi Code

InChI=1S/C24H24N2O5S2/c1-15-6-8-16(9-7-15)13-20-22(29)26(24(32)33-20)12-4-2-3-5-21(28)25-17-10-11-18(23(30)31)19(27)14-17/h6-11,13-14,27H,2-5,12H2,1H3,(H,25,28)(H,30,31)/b20-13-

SMILES Code

O=C(O)C1=CC=C(NC(CCCCCN(C/2=O)C(SC2=C/C3=CC=C(C)C=C3)=S)=O)C=C1O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

F1063-0967 is a Dual-specificity phosphatase 26 (DUSP26) inhibitor with an IC50 of 11.62 μM.

In vitro activity:

The inhibitory activity of F1063-0967 against DUSP26 is higher than that of NCS87877 (IC50 value: 16.67±2.89μM), but lower than that of ethyl-3, 4-dephostatin (IC50 value: 6.8±0.41μM). MTT assay results revealed that F1063-0967 can induce apoptosis in IMR-32 cell line with an IC50 value of 4.13μM. Reference: Biomed Pharmacother. 2017 May;89:376-385. https://pubmed.ncbi.nlm.nih.gov/28249240/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	206.36

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 484.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ren JX, Cheng Z, Huang YX, Zhao JF, Guo P, Zou ZM, Xie Y. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385. doi: 10.1016/j.biopha.2017.02.064. Epub 2017 Feb 27. PMID: 28249240.

In vitro protocol:

In vivo protocol:

TBD

1: Ren JX, Cheng Z, Huang YX, Zhao JF, Guo P, Zou ZM, Xie Y. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385. doi: 10.1016/j.biopha.2017.02.064. Epub 2017 Feb 27. PubMed PMID: 28249240.